Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31354869 | 0.88 | HTR2C (0.48) | HTR2CHTR2BHTR2A | |
| SCHEMBL31354888 | 0.87 | HTR2C (0.45) | HTR2CHTR2BCYP1A2CYP2C9HTR2A | |
| SCHEMBL14863103 | 0.87 | HRH4 (0.47) | HTR2CHTR2APOLBSMN1; SMN2 | |
| SCHEMBL21744587 | 0.82 | LRRK2 (0.37) | HTR2CLRRK2HTR2BMTORPIK3CD | |
| SCHEMBL10200468 | 0.80 | LRRK2 (0.43) | HTR2CLRRK2HTR2BCYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL2111490 | 0.79 | LRRK2 (0.42) | HTR2CLRRK2HTR2BCYP1A2CYP2C9 | |
| SCHEMBL31401032 | 0.78 | NOS3 (0.47) | LRRK2CYP1A2CYP2C9KDM4ELMNA | |
| SCHEMBL31400414 | 0.78 | KMT2A (0.36) | LRRK2CYP1A2CYP2C9MTORPIK3CD | |
| SCHEMBL5265623 | 0.77 | HTR2C (0.49) | HTR2CLRRK2HTR2BMTORKDM4E | |
| SCHEMBL31597918 | 0.77 | HTR2C (0.49) | HTR2CLRRK2HTR2BMTORKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| US-7091200-B2 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX U.S.A. LLC (US) | 2006-08-15 | — | — | US | disclosed |
| US-6900220-B2 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | disclosed |
| US-20050107365-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | BECKER CYRUS K (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1363899-B1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-05-11 | — | — | EP | disclosed |
| EP-1363899-A1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-26 | — | — | EP | disclosed |
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-04-10 | — | — | US | disclosed |
| WO-2002053558-A1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | F.HOFFMAN-LA ROCHE AG (CH) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | HTR2C 3385/4885LRRK2 1466/4885HTR2B 3054/4885 |
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | HTR2C 103/4885LRRK2 1987/4885HTR2B 64/4885 |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | HTR2C 3385/4885LRRK2 1466/4885HTR2B 3054/4885 |
| US-20050107365-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | HTR2C 97/4885LRRK2 2115/4885HTR2B 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.